girentuximab trade name rencarex chimeric monoclonal antibody carbonic anhydrase ix caix expressed surface renal cancer cells hypothesized surface tumor cells investigational agent clinical trials renal cell development suspended naked unconjugated antibody phase iii trials due girentuximab originally developed wilex ag germany granted fast track status orphan drug designation fda renal january telix pharmaceuticals limited australian biotechnology company announced inlicensed girentuximab use triggers antibodydependent cellmediated cytotoxicity adcc activating natural killer cells binding carbonic anhydrase monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikigirentuximab